



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# Sexually Transmitted Infection Prevention and Treatment

---

Kenneth H. Mayer, M.D.

The Fenway Institute, Beth Israel Deaconess Medical Center

# Disclosures

I have no financial disclosures.



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# Learning objectives


1. Describe the epidemiology of syphilis, chlamydia, gonorrhea, and other STIs among LGBTQ+ populations
2. Summarize optimal screening strategies for STIs.
3. Outline approaches to STI control that can be integrated into primary care.

# Caveats

- Many (most?) LGBTQ+ people do not face a high risk of STIs.
- Clinical care must be individualized, not based on group risk.
- Data about STIs among cisgender WSW and transgender/gender non-conforming people are limited.
- Terms that describe identity and behavior are imperfect and change over time.



# The rate of chlamydia diagnosis is increasing.




Sexually Transmitted Disease Surveillance 2017, CDC



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# Proportion of STI clinic patients testing positive for chlamydia




Sexually Transmitted Disease Surveillance 2017, CDC



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# The rate of gonorrhea diagnosis is increasing.




Sexually Transmitted Disease Surveillance 2017, CDC



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# MSM face an increasing disparity in the rate of gonorrhea.




Sexually Transmitted Disease Surveillance 2017, CDC



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# Antimicrobial resistance in gonorrhea is increasing.




Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance 2017*. Atlanta: U.S. Department of Health and Human Services; 2018.




ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

***Neisseria gonorrhoeae* — Percentage of Urethral Isolates with Elevated Azithromycin Minimum Inhibitory Concentrations (MICs) ( $\geq 2.0 \mu\text{g/ml}$ ) and Elevated Ceftriaxone MICs ( $\geq 0.125 \mu\text{g/ml}$ ) by Reported Sex of Sex Partners, Gonococcal Isolate Surveillance Project (GISP), 2011–2017**

**A. Azithromycin**




**B. Ceftriaxone**




\* No cases of elevated ceftriaxone MICs were reported among MSM in 2017.

**ACRONYMS:** MSM = Gay, bisexual, and other men who have sex with men (collectively referred to as MSM); MSW = Men who have sex with women only.

# The rate of syphilis diagnosis is increasing.



# A majority of new syphilis infections occur in MSM.



Sexually Transmitted Disease Surveillance 2017, CDC



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# **Some transgender people face a high burden of STIs.**

- **United States systematic review:**
  - STI lifetime prevalence = 21.1%, greater in MTF than FTM people
- **Prospective study of 230 MTF people New York City:**
  - Syphilis incidence 3.6% per year
  - Gonorrhea incidence 4.2% per year
  - Chlamydia incidence 4.5% per year
- **Retrospective study of 145 young people in Boston:**
  - Prevalence of syphilis 2.8%
  - Prevalence of gonorrhea and chlamydia 2.1% each

1. Herbst JH, Jacobs ED, Finlayson TJ, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. *AIDS Behav.* 2008;12(1):1.

2. Nuttbrock L, Bockting W, Rosenblum A, et al. Gender abuse, depressive symptoms, and HIV and other sexually transmitted infections among male-to-female transgender persons: a three-year prospective study. *Am J Public Health.* 2013;103(2):300.

3. Reisner SL, Vettes R, White JM, et al. Laboratory-confirmed HIV and sexually transmitted infection seropositivity and risk behavior among sexually-active transgender patients at an adolescent and young adult urban community health center. *AIDS Care.* 2015;27(8):1031.

# STIs are more than the “big three.”

- *Entamoeba histolytica* (Escola-Verge L, Euro Surveill, 2017)
- **Lymphogranuloma venereum** (De Baetselier I, BMC Infect Dis, 2018)
- Antibiotic-resistant *Shigella species* (Mook P, Emerg Infect Dis, 2016)
- **Meningococcus** (Folaranmi TA, Clin Infect Dis, 2017)
- **Hepatitis C** (Price JC, J Infect Dis, 2018)
- **Zika** (Rosenberg ES, J Infect Dis, 2018)



# *Mycoplasma genitalium*

- First identified in men with non-gonococcal urethritis (NGU) in 1980
- Major cause of NGU; more common than gonorrhea but less common than chlamydia
- Diagnosed by nucleic acid detection; culture challenging
- Treatment can be difficult:
  - Intrinsically resistant to beta-lactams
  - Doxycycline ineffective
  - Azithromycin increasingly ineffective
  - Moxifloxacin usually effective

Horner PJ, Martin DH. Mycoplasma genitalium infection in men. J Infect Dis. 2017;216(Suppl 2):S396-S405.

Workowski KA, Bolan G. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64(3).



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# Bacterial vaginosis is more common among WSW than other women.

- Among WSW, risk of BV is increased by:
  - Greater number of sexual partners (recent and lifetime)
  - BV in a partner
- Female partners often share identical Lactobacillus strains.
- Routine BV screening is not recommended for WSW.
- Empiric treatment for female partners of patients with BV is not formally recommended.


Vodstrcil, Clin Infect Dis, 2015; Forcey, PLoS One, 2015; Marrazzo, J Infect Dis, 2009; 2015 STD Treatment Guidelines



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH


# HPV and anal cancer among MSM

Figure 5. Anal HPV Infection by Age Group in Sexually Active HIV-negative MSM




Prevalence of human papillomavirus (HPV) DNA in the anal canals of HIV-negative men who have sex with men (MSM), by age group and by cancer-associated risk type. High-risk (HR) types include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73; low-risk types include 6, 11, 53-56, 66, Pap 155, and Pap 291.

Reprinted with permission from The University of Chicago Press.<sup>22</sup>



# Herpes simplex virus

- HSV-2 not clearly more common among MSM than other men in the United States.
- Anogenital herpes is often due to HSV-1 among MSM.
- HSV-1 and HSV-2 are becoming less common in the United States.




<sup>1</sup>Significant decreasing linear trend over time,  $p < 0.05$ .

NOTES: Age adjusted by the direct method to the 2000 U.S. Census population, using age groups 14–19, 20–29, 30–39, and 40–49 years. Total population includes all race and Hispanic-origin groups including those not shown separately. Data for the Asian subpopulation are only available since 2011, so this subpopulation is not shown separately, but included in the total population. Access data table for Figure 2 at:

[https://www.cdc.gov/nchs/data/databriefs/db304\\_table.pdf#2](https://www.cdc.gov/nchs/data/databriefs/db304_table.pdf#2)

SOURCE: NCHS, National Health and Nutrition Examination Survey, 1999–2016.



<sup>1</sup>Significant decreasing linear trend over time,  $p < 0.05$ .

NOTES: Age adjusted by the direct method to the 2000 U.S. Census population, using age groups 14–19, 20–29, 30–39, and 40–49 years. Total population includes all race and Hispanic-origin groups including those not shown separately. Data for the Asian subpopulation are only available since 2011, so this subpopulation is not shown separately, but included in the total population. Access data table for Figure 4 at:

[https://www.cdc.gov/nchs/data/databriefs/db304\\_table.pdf#4](https://www.cdc.gov/nchs/data/databriefs/db304_table.pdf#4)

SOURCE: NCHS, National Health and Nutrition Examination Survey, 1999–2016.



# Why are STI diagnoses increasing?

## Increased detection

Affordable Care Act (2010, 2014)

Extragenital gonorrhea and chlamydia testing


## Increased transmission

Smartphones and geosocial networking apps

HIV treatment as prevention


PrEP

# Minority Stress Model (adapted from Meyer)



Slide courtesy of Dr. Alex Keuroghlian

# Condom use is falling among MSM.




Paz-Bailey G, AIDS, 2016



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# Sexual histories should be routine and free of assumptions.



Partners



Practices



Past History  
of STDs



Protection  
from STDs



Pregnancy  
Plans

# STI prevention for LGBTQ+ people

1. Addressing socioeconomic factors that increase vulnerability
2. Vaccines – HAV, HBV, HPV
3. Condoms and risk-reduction counseling
4. PrEP for those at risk for HIV
5. STI screening and treatment – interrupting transmission prevents future infections



# What do we say about condoms in 2019?

- One item on a menu of options for HIV/STI prevention
- Condom counseling must adapt to the era of biobehavioral HIV prevention
- Advantages and disadvantages:
  - Protect against a wide range of STIs
  - Widely available; not a medical intervention
  - Use is apparent to partners
  - Efficacy is imperfect (as with all strategies); 70% effective at preventing HIV among MSM
  - Consistent condom use is rare
  - Some patients are unlikely to benefit from condoms (e.g., mutually monogamous serodifferent couple in which the partner living with HIV is virologically suppressed)

# CDC's screening recommendations for MSM

- HIV antibody/antigen assay
- Syphilis serology
- NAAT for *N. gonorrhoeae* and *C. trachomatis*
  - From the urethra/urine and rectum for both, if exposed
  - From the pharynx for *N. gonorrhoeae* only
- At least once: Hepatitis B surface antigen
- Yearly, if living with HIV: HCV antibody assays

2015 STD Treatment Guidelines




ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# Screening for transgender people and sexual minority women is based on risk assessment.

“Clinicians should assess STD- and HIV-related risks for their transgender patients **based on current anatomy and sexual behaviors**. Because of the diversity of transgender persons regarding surgical affirming procedures, hormone use, and their patterns of sexual behavior, providers must remain aware of symptoms consistent with common STDs and screen for asymptomatic STDs on the basis of behavioral history and sexual practices.”




# Syphilis testing follows a “traditional” or “reverse” testing algorithm.



# Causes of discordant syphilis test results in the “reverse” algorithm?

- Previously treated syphilis
- Old, untreated syphilis
- Very early syphilis (in a “window period” between treponemal antibody and RPR positivity, or the prozone phenomenon)



# What we know about gonorrhea and chlamydia testing in cisgender people

## CIS WOMEN

- NAATs are preferred.
- Sensitivity of first-catch urine is 10% less than a vaginal swab.
- A self-collected vaginal swab performs as well as a clinician-collected swab.
- Vaginal swabs perform as well as endocervical swabs.


## CIS MEN

- NAATs are preferred.
- Sensitivity of first-catch urine is the same as a urethral swab.

# Unanswered questions in STI screening for transgender people

- What is the risk of STIs in surgically-constructed vaginas and penises?
  - **Vaginoplasty techniques may involve urethral or colorectal mucosa, which is presumably susceptible to infection.**
- What is the optimal screening strategy for gonorrhea/chlamydia in the setting of genital reconstruction?
  - **Urine NAAT versus vaginal/urethral NAAT in vaginoplasty/phalloplasty**
  - **Some experts consider urine NAAT preferred.**
- Do STIs present differently in reconstructed tissue?
  - **Case report of neovaginal gonorrhea presenting as coital bleeding**

# PrEP may be an STI control intervention among MSM.



On PrEP,  
Reduce condom use by 40%


42% of gonorrhea and 40% of chlamydia infections  
prevented over 10 years

**SUMMARY OF THE 2015 CDC SEXUALLY TRANSMITTED DISEASE (STD) TREATMENT GUIDELINES**  
**MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH (MDPH) – DIVISION OF STD PREVENTION (DSTDp)**

These guidelines for treatment of STDs reflect recommendations of the **MDPH DSTDP** and of the **CDC STD Treatment Guidelines**. These guidelines focus on STDs encountered in outpatient settings and are not an exhaustive list of effective treatments. Please refer to the complete CDC document for more information or call the DSTDP. Clinical and epidemiological services are available through the DSTDP including staff to assist healthcare providers with confidential notification of sexual partners of patients with STDs and/or HIV infection. Please call the DSTDP for assistance at (617) 983-6940.

DISEASE	RECOMMENDED TREATMENT	ALTERNATIVES (use only if recommended regimens are contraindicated)
<b>SYphilis</b>		
ADULTS PRIMARY, SECONDARY OR EARLY LATENT (<1 YEAR)	<ul style="list-style-type: none"> <li>Benzathine penicillin G 2.4 million units IM once</li> </ul>	(For penicillin-allergic non-pregnant patients only) <ul style="list-style-type: none"> <li>Doxycycline 100 mg orally 2 times a day for 14 days <b>OR</b></li> <li>Tetracycline 500 mg orally 4 times a day for 14 days</li> </ul>
ADULTS LATE LATENT (>1 YEAR) OR LATENT OF UNKNOWN DURATION  <i>All Suspect Syphilis Cases:</i> Call the STD Program at (617) 983-6940 for past titers and treatment.	<ul style="list-style-type: none"> <li>Benzathine penicillin G 2.4 million units IM for 3 doses at 1 week intervals (total 7.2 million units)</li> </ul>	(For penicillin-allergic non-pregnant patients only) <ul style="list-style-type: none"> <li>Doxycycline 100 mg orally 2 times a day for 28 days <b>OR</b></li> <li>Tetracycline 500 mg orally 4 times a day for 28 days</li> </ul>
NEUROsyphilis including OCULAR SYphilis	<ul style="list-style-type: none"> <li>Aqueous crystalline penicillin G 18-24 million units per day, administered as 3-4 million units IV every 4 hours or continuous infusion, for 10-14 days<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>Procaine penicillin G 2.4 million units IM once daily <b>PLUS</b> probenecid 500 mg orally 4 times a day, both for 10-14 days</li> </ul>
CHILDREN PRIMARY, SECONDARY OR EARLY LATENT (<1 YEAR)	<ul style="list-style-type: none"> <li>Benzathine penicillin G 50,000 units/kg IM once, up to adult dose of 2.4 million units</li> </ul>	No specific alternative regimens exist.
CHILDREN LATE LATENT (>1 YEAR) OR LATENT OF UNKNOWN DURATION	<ul style="list-style-type: none"> <li>Benzathine penicillin G 50,000 units/kg IM (up to adult dose of 2.4 million units) for 3 doses at 1 week intervals (up to total adult dose of 7.2 million units)</li> </ul>	
CONGENITAL SYphilis	See complete CDC guidelines.	
HIV INFECTION	Same stage-specific recommendations as for HIV-negative persons.	
PREGNANCY	Penicillin is the <u>only</u> recommended treatment for syphilis during pregnancy. Women who are allergic should be desensitized and treated with penicillin. Treatment is the same as in non-pregnant patients for each stage of syphilis. <sup>2</sup>	
<b>GONOCOCCAL INFECTIONS</b>		
ADULTS, ADOLESCENTS AND CHILDREN >45 KG PHARYNGEAL, UROGENITAL, RECTAL	<ul style="list-style-type: none"> <li>Ceftriaxone 250 mg IM once <b>PLUS</b><sup>3</sup></li> <li>Azithromycin 1 g orally once</li> </ul>	<p><b>Note:</b> Use of an alternative regimen for pharyngeal gonorrhea should be followed by a test-of-cure 14 days after treatment.<sup>4</sup></p> <p><b>For urogenital or rectal infections ONLY, and ONLY if ceftriaxone is not available:</b></p> <ul style="list-style-type: none"> <li>Cefixime 400mg orally once <b>PLUS</b><sup>3</sup></li> <li>Azithromycin 1 g orally once <b>OR</b> in case of azithromycin allergy</li> <li>Doxycycline 100 mg orally 2 times a day for 7 days</li> </ul> <p><b>For azithromycin allergy:</b></p> <ul style="list-style-type: none"> <li>Ceftriaxone 250 mg IM once <b>PLUS</b><sup>3</sup></li> <li>Doxycycline 100 mg orally 2 times a day for 7 days</li> </ul> <p><b>For cephalosporin allergy or IgE-mediated penicillin allergy:</b></p> <ul style="list-style-type: none"> <li>Gemifloxacin 320 mg orally once <b>OR</b></li> <li>Gentamicin 240 mg IM once <b>PLUS</b><sup>3</sup></li> <li>Azithromycin 2 g orally once</li> </ul>

# Point-of-care testing for STIs may decrease transmission but shortening duration of infectivity.



## Amsterdam STI clinic modelling study:

- 35% of MSM had sexual contexts in the time between testing and treatment (23% of whom had CAS)
- POC testing for all MSM anticipated to decrease gonorrhea prevalence by 11% over 5 years

# What about anal cytology?

## YES

- Anal cancer is HPV-associated and exhibits biology similar to that of cervical cancer
- Rates of anal cancer are high in MSM, especially in those with HIV
- Recommended for all HIV-infected MSM

## NO


- As of yet, no randomized trials have been performed to assess the benefits of screening
- Whom to screen, how often, and when to start/stop screening are unclear

1. Silverberg MJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026-1034.

2. Aberg JA, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Disease Society of America. 2014;58(1):1-10.

# How to obtain anal cytology

- Place the patient in the lateral recumbent position.
- Insert a Dacron swab 5-6 cm into the anus.
- Apply lateral pressure and, while withdrawing the swab, rotate it.
- Submit the specimen as you would cervical cytology.





1. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR. 2010;59:RR-12.
2. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010;59(20):630-632.

## *HPV Vaccine Expanded for People Ages 27 to 45*



About 14 million women and men become infected with the human papillomavirus each year in the United States, according to the Centers for Disease Control and Prevention.  
Keith Bedford/The Boston Globe, via Getty Images

# Group B OMV meningococcal vaccine prevents gonorrhea infection.

- Mass vaccination against meningococcal group B infection in New Zealand from 2004-2008 (81% coverage of people < 20 years)
- Case control study of people ages 15-30 in sexual health clinics
  - Cases = Confirmed gonorrhea
  - Controls = Confirmed chlamydia
  - Exposure = Group B OMV meningococcal vaccination
- Vaccine effectiveness against gonorrhea = 31% (95% CI 21-39)


Petousis-Harris H, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603-1610.



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# Doxycycline PEP prevents syphilis and chlamydia among MSM.

- 232 MSM in a trial of open-label, on-demand PrEP with TDF-FTC
- Randomized to doxycycline within 24 hours of sex or no PEP
- Doxycycline reduced chlamydia and syphilis infections but not gonorrhea



Molina JM, Lancet Infect Dis, 2018



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

# PEP with doxycycline is generally well-tolerated.

	PEP (n=116)	No PEP (n=116)	p value
Any adverse events	106 (91%)	104 (90%)	0·65
Any serious adverse events	5 (4%)	10 (9%)	0·18
Any grade 3 or 4 events	4 (3%)	8 (9%)	0·24
Treatment discontinuation because of adverse events	8 (7%)	NA	..
Gastrointestinal adverse events	62 (53%)	47 (41%)	0·05
Drug-related gastrointestinal adverse events	29 (25%)	16 (14%)	0·03
Nausea or vomiting	10 (9%)	3 (3%)	..
Abdominal pain	14 (12%)	5 (4%)	..
Diarrhoea	6 (5%)	9 (8%)	..
Other gastrointestinal disorders	5 (4%)	1 (1%)	..

Molina JM, Lancet Infect Dis, 2018



ADVANCING EXCELLENCE IN SEXUAL  
AND GENDER MINORITY HEALTH

ORIGINAL ARTICLE

# Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

Stephanie N. Taylor, M.D., Jeanne Marrazzo, M.D., M.P.H.,  
Byron E. Batteiger, M.D., Edward W. Hook, III, M.D., Arlene C. Seña, M.D., M.P.H.,  
Jill Long, M.D., M.P.H., Michael R. Wierzbicki, Ph.D., Hannah Kwak, M.H.S.,  
Shaundra M. Johnson, B.S.P.H., Kenneth Lawrence, Pharm.D.,  
and John Mueller, Ph.D.



# Recap

- Provide LGBTQ+-affirming care
- Make the sexual history part of routine care
- Screen frequently, if the history indicates the need
- Vaccinate
- Consider doxycycline for MSM who have a high risk of STIs

